logo
CDC employees recount when gunman fired at least 180 shots at buildings: "Shocking but not surprising"

CDC employees recount when gunman fired at least 180 shots at buildings: "Shocking but not surprising"

CBS News9 hours ago
Centers for Disease Control and Prevention employees in Atlanta on Monday recalled the harrowing moment a gunman fired nearly 200 shots at multiple office buildings last week, killing a responding police officer.
Four CDC workers, who were not authorized to speak publicly, told CBS News under the condition of anonymity that they were "deeply disappointed and frustrated" by an apparent lack of leadership following Friday's shooting. Three of the four employees are mothers and all of them had differing experiences of the gunfire: one was inside a building standing in a window that would be later shot out, one was inside the daycare with her children, one was walking to their car and another was at home.
"I was walking to my car. I heard a very, very distinct and crisp pop, pop, pop, pop," one CDC employee said. "I knew that I had to get myself to safety because if I continued walking across the courtyard, I could potentially be in a killing field."
The pops heard were among at least 180 shots hitting at least 150 windows and doors on the CDC campus, according to two people with direct knowledge of the investigative findings from the ongoing probe of the shooting. Glass shards were propelled 30 to 60 feet into multiple rooms.
A second CDC worker said she wasn't sure at first whether the sounds she heard were construction noise or gunshots, then she saw a daycare teacher running with three kids. The noise changed when the bullets began hitting her building, she said. She recalled sheltering in place in her building for 2 hours without knowing where the gunman was.
The shooter, identified as 30-year-old Patrick Joseph White, died during the incident, police said. It remains unclear whether White died by self-inflicted gunshot or by police gunfire. His motive is still unknown at this stage of the investigation, Atlanta Mayor Andre Dickens said on Friday.
Several of White's neighbors told CBS News that he was outspokenly against vaccines, and a law enforcement source said authorities were looking into the possibility that the gunman believed the COVID-19 vaccines had made him sick.
When asked whether they "saw this" coming, another employee said, "I wouldn't say we saw it coming. I would say more that it wasn't a surprise."
"The CDC's been vulnerable for a really long time," she said. "It's shocking but not surprising."
The last employee told CBS News that she was leaving a daycare located in front of the CDC campus with her children and heading toward her car when they heard gunshots. She said she sprinted back into the daycare and hid with about eight children inside the bathroom, the only place without windows.
"My kids kept asking what was that loud popping noise," she said. "I'm still figuring out how this has affected my children."
Health and Human Services Secretary Robert F. Kennedy on Monday visited the CDC headquarters, seeing the damage and meeting with the widow of the police officer killed, David Rose.
In a statement on Monday, the HHS referred to Kennedy's remarks shared in his X post on Saturday: "We are deeply saddened by the tragic shooting at CDC's Atlanta campus that took the life of officer David Rose. We stand with his wife and three children and the entire CDC family."
At a news conference following Kennedy's visit, a spokesperson for the CDC Union AFGE Local 2883, which represents approximately 2,300 members, said the group found out about the shooting before the CDC sent a systemwide alert.
The union criticized Kennedy following his visit, saying, "He spent less time on the ground than the attacker did." They called for improved communication, as well as stepped up security, including 24/7 perimeter armed guards across campuses, installation of bulletproof glass, weapon detection measures and more extensive evacuation planning.
The CDC employees who spoke to CBS News said they expect more from the health secretary, hoping he would condemn the rhetoric that they believe led to the shooting.
"I think the challenge is that it would be hard for anyone to trust that he's sincere," one employee said in reference to Kennedy, who has been criticized for his past anti-vaccine statements. "He has been trashing ... the whole administration has been trashing the CDC and the work that we do."Anna Schecter
contributed to this report.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Daxor Corporation Announces Replay of Nasdaq Closing Bell Ceremony Now Available
Daxor Corporation Announces Replay of Nasdaq Closing Bell Ceremony Now Available

Yahoo

time24 minutes ago

  • Yahoo

Daxor Corporation Announces Replay of Nasdaq Closing Bell Ceremony Now Available

The celebration marks a major milestone for the patent-pending, next-generation, rapid, compact, and hand-held Daxor BVA™. Oak Ridge, TN, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement technology, today announces that the official replay of its Nasdaq Closing Bell Ceremony is now available. The ceremony, which took place on August 8, 2025, commemorated the FDA 510(k) clearance for its patent-pending, next-generation, rapid, compact, hand-held, lab-based new Daxor BVA™ (Blood Volume Analyzer). You can watch the full replay of the event here: Closing Ceremony. For more information, visit Sign up to receive news on Daxor's innovative technology HERE. About Daxor Corporation Daxor Corporation (NASDAQ: DXR) is tackling healthcare's "multi-billion-dollar silent crisis", the inability to precisely measure blood volume. This often results in suboptimal care, prolonged hospital stays, and increased readmissions for many high-cost medical conditions like heart failure and those requiring ICU care. With 50 years of experience and innovation, Daxor's patented, FDA-cleared Blood Volume Analysis (BVA) diagnostic offers unmatched, real-time, precise data via its rapid, hand-held, lab-based system. This empowers clinicians to make individualized treatment decisions that significantly improve patient outcomes and deliver substantial efficiencies in value-based healthcare. Daxor is ISO certified and operates a U.S.-based, 20,000-square-foot state-of-the-art manufacturing facility, positioning the company for accelerated market expansion. Forward-Looking Statements Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Investor Relations Contact:Investor Relations Contact:Bret ShapiroCOO – Head of Capital MarketsCOREIR(561)-479-8566-Cellbrets@ in to access your portfolio

Here's Why Halozyme Therapeutics (HALO) Traded Town in Q2
Here's Why Halozyme Therapeutics (HALO) Traded Town in Q2

Yahoo

time24 minutes ago

  • Yahoo

Here's Why Halozyme Therapeutics (HALO) Traded Town in Q2

Meridian Funds, managed by ArrowMark Partners, released its 'Meridian Growth Fund' second-quarter 2025 investor letter. A copy of the letter can be downloaded here. U.S. equity markets made a significant rebound during the quarter, increasing 23% from intra-period lows to close at record highs. Against this backdrop, the fund returned 4.10% (net) compared to the Russell 2500 Growth Index's 11.31% return. In addition, please check the fund's top five holdings to know its best picks in 2025. In its second-quarter 2025 investor letter, Meridian Growth Fund highlighted stocks such as Halozyme Therapeutics, Inc. (NASDAQ:HALO). Based in San Diego, California, Halozyme Therapeutics, Inc. (NASDAQ:HALO) is a biopharmaceutical company. The one-month return of Halozyme Therapeutics, Inc. (NASDAQ:HALO) was 11.11%, and its shares gained 12.32% of their value over the last 52 weeks. On August 11, 2025, Halozyme Therapeutics, Inc. (NASDAQ:HALO) stock closed at $62.89 per share, with a market capitalization of $7.356 billion. Meridian Growth Fund stated the following regarding Halozyme Therapeutics, Inc. (NASDAQ:HALO) in its second quarter 2025 investor letter: "Halozyme Therapeutics, Inc. (NASDAQ:HALO) is a leading drug delivery platform company built around its proprietary and commercially validated ENHANZE® technology. This innovative enzyme enables the subcutaneous delivery of biologics and fluids, transforming hours-long intravenous (IV) infusions into quick injections that can be delivered in just minutes. By doing so, ENHANZE can significantly reduce the treatment burden for patients and ease capacity constraints for healthcare providers. Shares of Halozyme declined during the period following news that the Centers for Medicare & Medicaid Services (CMS) may reconsider how it classifies reformulated drugs using ENHANZE. Under the proposed change, such formulations may no longer qualify as 'new drugs,' potentially subjecting them to Medicare price negotiations earlier than previously expected. While the proposal remains under review, we believe ENHANZE continues to offer meaningful advantages—including fewer injection-site reactions and substantial time and cost savings for clinics—making it an important innovation in drug delivery. We slightly reduced our position in the company during the quarter." An image of a research technician wearing lab coat with a syringe full of biopharmaceuticals. Halozyme Therapeutics, Inc. (NASDAQ:HALO) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 31 hedge fund portfolios held Halozyme Therapeutics, Inc. (NASDAQ:HALO) at the end of the first quarter, which was 25 in the previous quarter. In the second quarter of 2025, Halozyme Therapeutics, Inc. (NASDAQ:HALO) reported revenue of $326 million, representing 41% year-over-year increase. While we acknowledge the potential of Halozyme Therapeutics, Inc. (NASDAQ:HALO) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. In another article, we covered Halozyme Therapeutics, Inc. (NASDAQ:HALO) and shared the list of most undervalued biotech stocks to buy. Halozyme Therapeutics, Inc. (NASDAQ:HALO) rose in the previous quarter due to strong earnings and its decision to focus on its core business. In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Mario and Courtney Lopez Team Up with NaturVet to Spotlight Award-Winning Pet Supplements at SuperZoo 2025
Mario and Courtney Lopez Team Up with NaturVet to Spotlight Award-Winning Pet Supplements at SuperZoo 2025

Yahoo

time24 minutes ago

  • Yahoo

Mario and Courtney Lopez Team Up with NaturVet to Spotlight Award-Winning Pet Supplements at SuperZoo 2025

The duo will showcase NaturVet's offerings, led by All-In-One Daily Care, recently named "Dog Vitamin/Supplement Innovation of the Year" LAS VEGAS, Aug. 12, 2025 /PRNewswire/ -- Mario and Courtney Lopez are joining NaturVet at SuperZoo 2025 to celebrate the brand's refreshed look and inspire pet parents to take a proactive approach to their pets' health and wellness. The show is August 13-15 at Mandalay Bay Convention Center, and the beloved television personalities will appear at booth #9747 on day two for a media/VIP event. "Having Mario and Courtney Lopez join us at SuperZoo is incredibly exciting," said Geoff Granger, CEO at NaturVet. "We share a passion for helping pets live healthier, happier lives, and their involvement allows us to extend this message to even more pet parents." NaturVet's All-In-One Daily Care line was recently named "Dog Vitamin/Supplement Innovation of the Year" by the 2025 Pet Innovation Awards, a prestigious program that recognizes the most innovative companies, services and products in the global pet industry. With comprehensive, vet-formulated benefits and easy-to-give soft chews, the All-In-One line stood out for delivering real results for dogs at every life stage, from puppyhood through their senior years. NaturVet will showcase its award-winning All-In-One Daily Care line at SuperZoo, along with a range of new product innovations including: All-In-One Puppy Daily Care: A soft chew supplement with a hickory smoked bacon flavor designed to support the needs of growing puppies with six essential key benefits, including skeletal support, brain development, healthy digestion and immune health. Formulated for younger dogs, it features the exclusive dental care ingredient PlaqueOff® for added oral health support. All-In-One Adult Daily Care: A 10-in-1 soft chew supplement designed to support adult dogs with targeted benefits, including joint health, digestion, immunity, skin and coat health and more. Featuring a delicious hickory smoked bacon flavor and the exclusive dental care ingredient PlaqueOff®, it helps support overall health and well-being throughout adulthood. All-In-One Senior Daily Care: An 8-in-1 soft chew supplement designed to support aging dogs by targeting areas such as joint health, mobility and gut health, while also providing brain, heart and vision support. It features the exclusive ingredient PlaqueOff® for dental care and tailored ingredients that help support longevity and immunity. With its hickory smoked bacon flavor, the soft chews are easy to give to senior dogs. Lickable Supplements for Cats: A pump-dispensed supplement designed for easy dosing. Available in Hip & Joint, Calming and Multi-Vitamin formulas, it provides essential support in a mess-free format, making supplementation effortless for cat owners. Lickable Supplements for Dogs: A peanut butter-flavored supplement for dogs, available in Hip & Joint, Calming and Multi-Vitamin formulas. Designed for easy dosing with a pump, it offers a convenient, mess-free alternative to traditional supplements while addressing key dog health and wellness needs. SuperZoo attendees are invited to stop by booth #9747 to meet the NaturVet team, explore some of their best-selling products and see how the Lopez family is partnering with NaturVet to inspire happier, healthier pets. To learn more about NaturVet and its complete line of vet-formulated supplements, visit About NaturVet NaturVet is a 30-year pioneer and present-day innovator manufacturing high-quality pet products designed to support the health, wellness and quality of life for pets and pet parents. Headquartered in Southern California, NaturVet produces dog, cat and equine supplements including all-in-one vitamins and targeted solutions for calming, digestion, allergy aids, skin and joint support. Formulated by veterinarians and manufactured in-house to ensure quality, NaturVet's products are made with ingredients which are sourced from trusted global suppliers and tested to meet rigorous standards by the National Animal Supplement Council (NASC). For more information, visit View original content to download multimedia: SOURCE NaturVet Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store